98%
921
2 minutes
20
The substituent design and photophysical property manipulation are of paramount importance in fluorescent probe design, particularly crucial for chemically inactive molecules that lack reactive functional groups, such as synthetic cannabinoids. Here, a ratiometric fluorescent probe, 2-(5-phenyl-8-(4-(trifluoromethyl)phenyl)pyrimido[4,5-]pyridazin-2-yl)phenol (DPTF), was selected and synthesized using trifluoromethyl as an electron acceptor for the sensitive and specific detection of one representative synthetic cannabinoid, JWH-018 (1-naphthyl(1-pentyl-1H-indol-3-yl)methanone). The DPTF probe, driven by intermolecular through-space charge transfer (TSCT), exhibits a theoretically calculated limit of detection (LOD) of 2.16 nmol/mL to liquid JWH-018, with low naked-eye detection limits of 101 nmol/mL for liquid JWH-018 and 147 nmol/mL on the porcelain spot plate, and also demonstrates good anti-interference capabilities with 18 substances. The practicability of the probe was further verified through testing E-liquid, urea, artificial saliva, local sewage, and cigarettes, successfully detecting trace amounts of impure JWH-018 in both simulated and real scenarios. Moreover, this work contributes to the probe design methods to understand the photophysical mechanisms that dominate molecular recognition, and we expect that the detection of synthetic cannabinoids is essential for comprehending their epidemiological spread and preventing incidents related to drug-impaired driving or violence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.analchem.5c02786 | DOI Listing |
Expert Opin Pharmacother
September 2025
Department of Psychiatry, University of Calgary.
Introduction: Cannabis use disorder (CUD) is a growing global health concern, with limited pharmacological treatments currently available despite increasing prevalence and legalization trends.
Areas Covered: This review explores the landscape of pharmacotherapies for CUD, including both repurposed agents and emerging investigational compounds. We summarize findings from recent systematic reviews and meta-analyses, with attention to mechanisms of action and clinical relevance.
Clin Toxicol (Phila)
August 2025
Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, Australia.
Introduction: Seizures are a marker of severe toxicity following overdose. Research characterising toxicological seizures is limited. We aim to study toxicological seizures, causative agents, and recurrence.
View Article and Find Full Text PDFCureus
July 2025
Department of Periodontology, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Navi Mumbai, IND.
Cannabis and its bioactive compounds, specifically tetrahydrocannabinol and cannabidiol, are rapidly growing in popularity for their therapeutic applications across a variety of medical specialties, including dentistry. This narrative review aims to explore the current and future applications of cannabinoids in dentistry and the therapeutic potential, problems, and ethical issues. Cannabinoids possess analgesic, anti-inflammatory, anxiolytic, and neuroprotective properties that may be beneficial in the treatment of orofacial neuropathic pain, temporomandibular joint disorders, myofascial pain dysfunction syndrome, bruxism, and obstructive sleep apnea.
View Article and Find Full Text PDFJ Chromatogr A
October 2025
Institute of Forensic Medicine, Department of Biomedical Engineering, University of Basel, Basel, Switzerland. Electronic address:
∆-tetrahydrocannabinol (∆-THC) plays a major role in driving under the influence of drugs investigations and workplace drug testing. Additionally, cannabidiol (CBD), as well as semi-synthetic cannabinoids, like hexahydrocannabinol (HHC) and ∆-tetrahydrocannabinol (∆-THC), are increasingly found on regulated and unregulated drug markets. A straightforward bioanalytical method was developed, covering 14 analytes, including ∆-THC, CBD, ∆-THC, and their respective metabolites, as well as HHC and a subset of minor phytocannabinoids.
View Article and Find Full Text PDFPharmaceuticals (Basel)
July 2025
Institute for Research and Community Service, State Islamic University of Sunan Kalijaga (UIN Sunan Kalijaga), Yogyakarta 55281, Indonesia.
: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed type 2 diabetes mellitus (T2DM) management by promoting glucosuria, lowering glycated hemoglobin (HbA1c), blood pressure, and weight; however, their use is limited by genitourinary infections and ketoacidosis. Phytocannabinoids-bioactive compounds from -exhibit multi-target pharmacology, including interactions with cannabinoid receptors, Peroxisome Proliferator-Activated Receptors (PPARs), Transient Receptor Potential (TRP) channels, and potentially SGLT2. : To evaluate the potential of phytocannabinoids as novel modulators of renal glucose reabsorption via SGLT2 and to compare their efficacy, safety, and pharmacological profiles with synthetic SGLT2 inhibitors.
View Article and Find Full Text PDF